Skye Bioscience (SKYE) Change in Account Payables (2015 - 2026)
Skye Bioscience (SKYE) posted quarterly Change in Account Payables of $1.9 million for Q1 2026, up 56.57% year-over-year from $1.2 million in Q1 2025, and up 340.47% quarter-over-quarter from -$791574.0 in Q4 2025.
Skye Bioscience (SKYE) Change in Account Payables (2015 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Change in Account Payables for 12 consecutive years, with $1.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 56.57% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $2.1 million (up 201.95% YoY), while the FY2025 annual figure was $1.4 million, up 337.91% from the prior year.
- Change in Account Payables advanced to $1.9 million in Q1 2026 per SKYE's latest filing, from -$791574.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.9 million in Q1 2026 and bottomed at -$791574.0 in Q4 2025.
- Historically, Change in Account Payables has averaged $158763.6 across 5 years, with a median of -$15640.0 in 2024.
- Annual changes were most pronounced in 2023 — Change in Account Payables tumbled 2136.46% — and 2025, when it soared 8851.46%.
- Skye Bioscience's Change in Account Payables stood at -$258665.0 in 2022, then soared by 95.63% to -$11300.0 in 2023, then sank by 1765.25% to -$210773.0 in 2024, then tumbled by 275.56% to -$791574.0 in 2025, then soared by 340.47% to $1.9 million in 2026.
- Business Quant data shows SKYE's Change in Account Payables at $1.9 million in Q1 2026, -$791574.0 in Q4 2025, and -$397505.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Skye Bioscience | 10.86 Mn | 10.86 Mn | - | 341,471.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.90 Mn |
| Mar 31, 2026 | 1.90 Mn |
| Dec 31, 2025 | -791,574.00 |
| Dec 31, 2025 | -791,574.00 |
| Sep 30, 2025 | -397,505.00 |
| Sep 30, 2025 | -397,505.00 |
| Jun 30, 2025 | 1.37 Mn |
| Jun 30, 2025 | 1.37 Mn |
| Mar 31, 2025 | 1.22 Mn |
| Mar 31, 2025 | 1.22 Mn |
| Dec 31, 2024 | -210,773.00 |
| Dec 31, 2024 | -210,773.00 |
| Sep 30, 2024 | -299,468.00 |
| Sep 30, 2024 | -299,468.00 |
| Jun 30, 2024 | -15,640.00 |
| Jun 30, 2024 | -15,640.00 |
| Mar 31, 2024 | -60,652.00 |
| Mar 31, 2024 | -60,652.00 |
| Dec 31, 2023 | -11,300.00 |
| Dec 31, 2023 | -11,300.00 |